Loading...

ADC Therapeutics SA (NYSE:ADCT)

8.02 USD +0.13 USD ( +1.65% )
Watchlist Manager
ADC Therapeutics SA
NYSE:ADCT
Watchlist

EV/S
Enterprise Value to Sales

The Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.

EV/S
=
Enterprise Value
/
Revenue
Current EV/S
ADCT
6
Median EV/S
ADCT
N/A
Industry EV/S
Biotechnology
8.5

EV/S History

Statistics
Enterprise Value to Sales

1 Year 3 Years 5 Years
Average 135.2 47.5 28.8
Median 41.2 N/A N/A
Min N/A N/A N/A
Max 523.9 523.9 523.9

History Chart
Enterprise Value to Sales

EV/S Forward Multiples

Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/S
3.7
2-Years Forward
EV/S
3
3-Years Forward
EV/S
1.6

EV/S Across Competitors

ADCT Competitors
ADC Therapeutics SA Competitors

Country Company Market Cap EV/S
CH
ADC Therapeutics SA
NYSE:ADCT
616M USD 6
US
Abbvie Inc
NYSE:ABBV
271B USD 5.8
US
Amgen Inc
NASDAQ:AMGN
131B USD 6.1
AU
CSL Ltd
ASX:CSL
130B AUD 8.4
US
Gilead Sciences Inc
NASDAQ:GILD
78.9B USD 3.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
73.4B USD 8.3

Relative Valuation Report

View full relative valuation report for ADC Therapeutics SA, which takes into account all ADCT`s valuation multiples.

See Also

Similar Stocks